A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Glucotrack, Inc.
GCTK
$57
Mkt Cap
$0.29
-6.67%
Glucotrack, Inc. (GCTK) has a current P/E ratio of 0.0.
Glucotrack, Inc. (GCTK) has a 5-year average return on invested capital (ROIC) of -102.4%. This is below average and may indicate limited pricing power.
Glucotrack, Inc. (GCTK) has a market capitalization of $265K. It is classified as a small-cap stock.
Glucotrack, Inc. (GCTK) does not currently pay a regular dividend.
Glucotrack, Inc. (GCTK) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
Glucotrack, Inc. (GCTK) generated $-4 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Glucotrack, Inc. (GCTK) has a debt-to-equity ratio of 0.02. This indicates a conservatively financed balance sheet.
Item 1. Business Unless the context otherwise requires, the terms “we”, “our”, “ours” “us”, “Company” and “Glucotrack” refer to Glucotrack, Inc., a Delaware corporation. The Company was incorporated on May 18, 2010 under the laws of the State of Delaware. We are a medical device company focused on the development of an implantable continuous blood glucose monitor (“CBGM”) for persons with Type 1 diabetes and insulin-dependent Type 2 diabetes (the “Glucotrack CBGM”). The Company was founded with a mission to develop Glucotrack®, a non-invasive glucose monitoring device designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain, inconvenience, cost and difficulty of conventional (invasive) spot finger stick devices. The first generation Glucotrack, which successfully received CE Mark approval, obtained glucose measurements via a small sensor clipped onto one’s earlobe.
| Metric | TTM | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | - | - | - |
| Net Income | -19M | -2.7M | -3.5M | -40M | -12M | -6.2M |
| EPS | $-23.58 | $14,820.00 | $-5.20 | $-4.30 | $-28.60 | $-16.52 |
| Free Cash Flow | -15M | -3.6M | -3.9M | -4.9M | -5.9M | -5.4M |
| ROIC | -781.3% | -23.3% | 252.7% | -750.6% | 500.6% | -181.6% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 2.19 | 0.02 | -0.13 | -1.24 | -0.00 | -0.00 |
| Dividends/Share | $0.00 | - | - | - | $0.01 | $0.04 |
| Operating Income | -16M | -3.1M | 3.5M | -6.5M | 11M | -5.7M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | -685.6% | -30.0% | 164.1% | 409.5% | 85.5% | 69.5% |
| Shares Outstanding | 1M | 0M | 1M | 9M | 0M | 0M |
| Metric | 2004 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | N/A | 0 | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0 |
| Gross Margin | 0.0% | 0.0% | 0.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | N/A | 1.9M | 2.0M | 1.8M | 2.3M | 2.9M | 3.2M | 3.0M | 1.6M | 1.5M | 9.8M |
| SG&A | N/A | 853K | 1.0M | 231K | 1.1M | 1.1M | 1.5M | 2.5M | 1.5M | 1.2M | 6.3M |
| EBIT | N/A | -2.8M | -3.0M | -3.6M | -4.7M | -5.7M | 11M | -6.5M | 3.5M | -3.1M | -16M |
| Op. Margin | 0.0% | 0.0% | 0.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Net Income | -288K | -2.8M | -10M | 2.0M | -6.3M | -6.2M | -12M | -40M | -3.5M | -2.7M | -19M |
| Net Margin | 0.0% | 0.0% | 0.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 146K | 121K | 79K | 24K | 24K |
| Returns on Capital | |||||||||||
| ROIC | N/A | N/M | -86.8% | -37.1% | -172.4% | -181.6% | N/M | N/M | N/M | -23.3% | N/M |
| ROE | N/A | -1192.0% | N/A | -24.8% | 106.6% | 69.5% | 85.5% | 409.5% | 164.1% | -30.0% | -685.6% |
| ROA | N/A | -185.0% | -580.5% | 43.3% | -148.3% | -271.1% | -569.7% | -3378.6% | -394.1% | -25.4% | -247.4% |
| Cash Flow | |||||||||||
| Op. Cash Flow | 0 | -12M | -3.2M | 3.4M | -4.6M | -5.3M | -5.9M | -4.9M | -3.9M | -3.5M | -15M |
| Free Cash Flow | N/A | -12M | -3.3M | 3.3M | -4.7M | -5.4M | -5.9M | -4.9M | -3.9M | -3.6M | -15M |
| Owner Earnings | 0 | -12M | -3.5M | 3.3M | -4.6M | -5.4M | -8.6M | -5.7M | -4.3M | -3.6M | -15M |
| CapEx | 0 | 11K | 64K | 63K | 144K | 76K | 19K | 5K | 23K | 53K | 96K |
| Maint. CapEx | 0 | 154K | 198K | 35K | 45K | 60K | 68K | 59K | 51K | 47K | 42K |
| Growth CapEx | N/A | 0 | 0 | 29K | 99K | 17K | 0 | 0 | 0 | 6K | 54K |
| D&A | 0 | 154K | 198K | 35K | 45K | 60K | 68K | 59K | 51K | 47K | 42K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||||
| Dividends Paid | 0 | 0 | 288K | 370K | 57K | 14K | 6K | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | 0.0% | 0.0% | 0.0% | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | N/A | N/A | N/A | N/A | N/A | 0.0% | 0.0% |
| Stock-Based Comp | N/A | 350K | 36K | 50K | 18K | 70K | 2.7M | 705K | 356K | 22K | 211K |
| Debt Repayment | 0 | 36K | 39K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||||||
| Net Debt | N/A | -895K | -2.8M | -5.8M | -570K | -110K | -11K | N/A | -232K | -19M | -1.2M |
| Cash & Equiv. | N/A | 543K | 2.4M | 5.8M | 609K | 149K | 54K | 97K | 419K | 9.8M | 7.4M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 3.0M |
| Debt/Equity | N/A | -0.07 | 0.00 | -0.02 | -0.01 | -0.00 | -0.00 | -1.24 | -0.13 | 0.02 | 2.19 |
| Interest Coverage | N/A | -13.8 | -172.1 | -1647.9 | -306.2 | -348.8 | 433.5 | -357.5 | 81534.9 | N/A | N/A |
| Equity | -488K | -503K | -11M | -4.8M | -7.0M | -11M | -17M | -2.9M | -1.4M | 9.0M | 2.8M |
| Total Assets | N/A | 815K | 2.8M | 6.3M | 2.1M | 2.5M | 1.7M | 688K | 1.1M | 11M | 7.8M |
| Total Liabilities | N/A | 1.3M | 14M | 3.4M | 9.1M | 13M | 18M | 3.6M | 2.5M | 1.6M | 5.0M |
| Intangibles | 0 | 0 | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | N/A | -15M | -26M | -23M | -29M | -36M | -47M | -87M | -91M | -93M | -152M |
| Working Capital | N/A | 167K | 2.2M | 5.0M | 202K | -331K | -2.5M | -2.9M | -1.6M | 8.9M | 2.9M |
| Current Assets | N/A | 625K | 2.5M | 6.0M | 1.7M | 2.0M | 1.2M | 314K | 718K | 10M | 7.7M |
| Current Liabilities | N/A | 458K | 311K | 1.0M | 1.5M | 2.3M | 3.7M | 3.2M | 2.3M | 1.3M | 4.8M |
| Per Share Data | |||||||||||
| EPS | N/A | -3,120.00 | -11,700.00 | 5.66 | -17.59 | -16.52 | -28.60 | -4.30 | -5.20 | 14,820.00 | -23.58 |
| Owner EPS | N/A | -13,592.59 | -3,897.03 | 9.41 | -12.94 | -14.43 | -20.99 | -0.61 | -6.37 | -18,017.34 | -17.01 |
| Book Value | N/A | -566.16 | -12,490.01 | -13.88 | -19.49 | -29.04 | -40.29 | -0.31 | -2.09 | 45,331.03 | 3.11 |
| Cash Flow/Share | N/A | -13,025.64 | -3,632.79 | 9.66 | -12.77 | -14.09 | -14.33 | -0.53 | -5.77 | -17,669.11 | -21.24 |
| Dividends/Share | N/A | N/A | 325.43 | 1.06 | 0.16 | 0.04 | 0.01 | N/A | N/A | N/A | 0.00 |
| Shares Out. | N/A | 0.0M | 0.0M | 0.3M | 0.4M | 0.4M | 0.4M | 9.3M | 0.7M | 0.0M | 0.9M |
| Valuation | |||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -0.0 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.1 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | N/A | N/A | N/A | N/A | -26.5% | -43.0% | -2.1% | -4.9% | -3.7% | N/A | -5783.0% |
| Market Cap | 0 | 0 | 0 | 0 | 18M | 13M | 286M | 100M | 105M | 0 | 265K |
| Avg. Price | 0.00 | 0.00 | 0.00 | 0.00 | 393,342.86 | 264,154.86 | 228,410.82 | 109,758.69 | 30,912.45 | 0.00 | 0.29 |
| Year-End Price | 0.00 | 0.00 | 0.00 | 0.00 | 273,000.00 | 195,000.00 | 152,100.00 | 39,000.00 | 46,800.00 | 0.00 | 0.29 |
Glucotrack, Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
Glucotrack, Inc. (GCTK) reported earnings per share (EPS) of $14820.00 in its most recent fiscal year.
Glucotrack, Inc. (GCTK) has a return on equity (ROE) of -30.0%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 10 years of financial data for Glucotrack, Inc. (GCTK), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Glucotrack, Inc. (GCTK) has a book value per share of $45331.03, based on its most recent annual SEC filing.